As of June 16, 2025, Medpace Holdings Inc (MEDP) reports a Gross Margin of 31.12%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of Medpace Holdings Inc's Gross Margin
Over recent years, Medpace Holdings Inc's Gross Margin has shown a moderate pattern. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2024-12-31 | 31.12% |
| 2023-12-31 | 27.81% |
| 2022-12-31 | 29.62% |
| 2021-12-31 | 28.73% |
| 2020-12-31 | 30.10% |
This slight downward trend highlights how Medpace Holdings Inc manages its operational efficiency and pricing power over time.
Comparing Medpace Holdings Inc's Gross Margin to Peers
To better understand Medpace Holdings Inc's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Medpace Holdings Inc (MEDP) | 31.12% |
| Abcellera Biologics Inc (ABCL) | 7775.20% |
| Inotiv Inc (BASI) | 3015.93% |
| Replicel Life Sciences Inc (RP.V) | 100.00% |
| Quick-Med Technologies Inc (QMDT) | 97.31% |
| Codexis Inc (CDXS) | 72.55% |
Compared to its competitors, Medpace Holdings Inc's Gross Margin is about average compared to peers, indicating industry-standard operational efficiency.